Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus

Clinical Infectious Diseases

Volumn 44, Issue 12, 2007, Pages 1536-1542

  Mohr, John F ^a   Murray, Barbara E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; ORITAVANCIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIUM ISOLATION; BLOOD CULTURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; TREATMENT INDICATION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 34249874084     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518451     Document Type: Conference Paper

References (45)

1. Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42(Suppl 1): S5-12.
2. Nathwani D, Tillotson GS. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era? Int J Antimicrob Agents 2003; 21:521-4.
3. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. Standard M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
4. Vancocin (vancomycin injection, USP) prescribing information. Deerfield, IL: Baxter Healthcare, 2003.
5. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39:539-45.
6. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
7. Perichon B, Courvalin P. Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:4281-5.
8. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:624-6.
9. Song JH, Hiramatsu K, Suh JY, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48:4926-8.
10. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51.
11. Turner J, Howe RA, Wootton M, et al. The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model. J Antimicrob Chemother 2001; 48:727-30.
12. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47:1262-6.
13. Tsuji BT, Rybak Ml, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1089-91.
14. Kropec A, Daschner FD. Penetration into tissues of various drugs active against gram-positive bacteria. J Antimicrob Chemother 1991; 27(Suppl B):9-15.
15. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38:865-9.
16. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97:344-50.
17. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-402.
18. Sakoulas G, Eliopoulos GM, Fowler VG, Jr, et al. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother 2005; 49:2687-92.
19. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Mocllering RC Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-5.
20. Ebert S. In vitro cidal activity and pharmacokinetic parameters for vancomycin against methicillin-susceptible and resistant S. aureus [abstract 439]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington, DC: American Society for Microbiology, 1987.
21. Craig W, Andes D. In vivo pharmacodynamics of vancomycin against VISA, hctcroresistant VISA (hVISA) and VSSA in the neutropenic murine thigh-infection model [abstract A-644]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
22. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinct 2004; 43:925-42.
23. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55.
24. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44.
25. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42(Suppl 1):S13-24.
26. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-VISA, vancomycin susceptible clinical MRSA blood isolates from 2001-2005 [abstract A-084]. In: Program and abstracts of the 106th Annual Meeting of the American Society for Microbiology (Orlando, FL). Washington, DC: American Society for Microbiology, 2006.
27. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
28. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-23.
29. Matzke GR, McGory RW, Halstenson CE, Keane WF Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25:433-7.
30. Mocllering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981; 94:343-6.
31. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
32. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6.
33. Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. Int J Antimicrob Agents 2006; 27:259-62.
34. Arbeit RD, Maki D, Tally FP, Campanaro F, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
35. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601-7.
36. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41(Suppl 5):S341-53.
37. Giamarellou H, O'Riordan W, Harris H, Owen S, Porter S, Louth J. Phase 3 trial comparing 3-7 days of oritavancin vs. 10-14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections (cSST1) [abstract L-739a]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003.
38. Noel G, Strauss S, Pypstra R. Successful treatment of complicated skin infections due to staphylococci, including methicillin-resistant Staphylococcus aureus with ceftobiprole [abstract L-1212]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 2006.
39. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-15.
40. Cui L, Tominaga E, Neoh HM, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:1079-82.
41. Sakoulas G, Alder I, Thauvin-Eliopoulos C, Mocllering RC Jr, Eliopoulos GM. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581-5.
42. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
43. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
44. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
45. Wootton M, Walsh TR, MacGowan AP. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:3982-3.